Allogeneic BCMA CAR-T Cell Therapy for the Treatment of Multiple Myeloma

Time: 3:30 pm
day: Day One


  • Developing the first allogeneic cell therapy for R/R multiple myeloma – from
    bench to bedside
  • Enhancing potency and persistence of allogeneic BCMA CAR-T cells with TurboCARs
  • Testing the promise of TurboCAR technology in the clinic